TARA-002 + Investigator's Choice of Intravesical Chemotherapy
Phase 3RecruitingDevelopment Stage
Bladder (Urothelial, Transitional Cell) Cancer
Bladder (Urothelial, Transitional Cell) Cancer, Non-Muscle Invasive Bladder Carcinoma, Non-muscle Invasive Bladder Cancer With Carcinoma in Situ
May 1, 2026 → Nov 1, 2032
About TARA-002 + Investigator's Choice of Intravesical Chemotherapy
TARA-002 + Investigator's Choice of Intravesical Chemotherapy is a phase 3 stage product being developed by Protara Therapeutics for Bladder (Urothelial, Transitional Cell) Cancer. The current trial status is recruiting. This product is registered under clinical trial identifier NCT07480356. Target conditions include Bladder (Urothelial, Transitional Cell) Cancer, Non-Muscle Invasive Bladder Carcinoma, Non-muscle Invasive Bladder Cancer With Carcinoma in Situ.
What happened to similar drugs?
10 of 20 similar drugs in Bladder (Urothelial, Transitional Cell) Cancer were approved
Hype Score Breakdown
Clinical Trials (1)
| NCT ID | Phase | Status |
|---|---|---|
| NCT07480356 | Phase 3 | Recruiting |
Competing Products
20 competing products in Bladder (Urothelial, Transitional Cell) Cancer